非酒精性脂肪性肝病中的核受体
Nuclear receptors in nonalcoholic Fatty liver disease.
作者信息
López-Velázquez Jorge A, Carrillo-Córdova Luis D, Chávez-Tapia Norberto C, Uribe Misael, Méndez-Sánchez Nahum
机构信息
Liver Research Unit, Medica Sur Clinic & Foundation, Puente de Piedra 150, Colonia Toriello Guerra, 14050 Tlalpan, Mexico City, Mexico.
出版信息
J Lipids. 2012;2012:139875. doi: 10.1155/2012/139875. Epub 2011 Dec 8.
Nuclear receptors comprise a superfamily of ligand-activated transcription factors that are involved in important aspects of hepatic physiology and pathophysiology. There are about 48 nuclear receptors in the human. These nuclear receptors are regulators of many hepatic processes including hepatic lipid and glucose metabolism, bile acid homeostasis, drug detoxification, inflammation, regeneration, fibrosis, and tumor formation. Some of these receptors are sensitive to the levels of molecules that control lipid metabolism including fatty acids, oxysterols, and lipophilic molecules. These receptors direct such molecules to the transcriptional networks and may play roles in the pathogenesis and treatment of nonalcoholic fatty liver disease. Understanding the mechanisms underlying the involvement of nuclear receptors in the pathogenesis of nonalcoholic fatty liver disease may offer targets for the development of new treatments for this liver disease.
核受体构成了一个配体激活的转录因子超家族,参与肝脏生理和病理生理的重要方面。人类大约有48种核受体。这些核受体是许多肝脏过程的调节因子,包括肝脏脂质和葡萄糖代谢、胆汁酸稳态、药物解毒、炎症、再生、纤维化和肿瘤形成。其中一些受体对控制脂质代谢的分子水平敏感,包括脂肪酸、氧化甾醇和亲脂性分子。这些受体将此类分子导向转录网络,并可能在非酒精性脂肪性肝病的发病机制和治疗中发挥作用。了解核受体参与非酒精性脂肪性肝病发病机制的潜在机制,可能为开发这种肝病的新治疗方法提供靶点。
相似文献
J Lipids. 2012
Hepatology. 2011-2-11
Free Radic Biol Med. 2013-8-29
Mol Aspects Med. 2017-8
Biomed Pharmacother. 2020-1
Dig Dis. 2010-5-7
World J Hepatol. 2015-12-8
引用本文的文献
Elife. 2021-12-29
Toxicology. 2022-1-30
PLoS One. 2020-10-1
J Med Chem. 2020-3-20
Toxicol Appl Pharmacol. 2019-1-3
本文引用的文献
Hepatology. 2011-2-11
Clin Pharmacol Ther. 2010-3-3
Curr Drug Metab. 2008-9
Expert Opin Drug Metab Toxicol. 2008-7
Drug Metab Pharmacokinet. 2008